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To identify genetic loci for severe diabetic retinopathy, 286 Mexican-Americans with type 2 diabetes from Starr County, Texas,
completed physical examinations including fundus photography for diabetic retinopathy grading. Individuals with moderate-to-
severe non-proliferative and proliferative diabetic retinopathy were deﬁned as cases. Direct genotyping was performed using the
Aﬀymetrix GeneChip Human Mapping 100K Set, and SNPs passing quality control criteria were used to impute markers available
in HapMap Phase III Mexican population (MXL) in Los Angeles, California. Two directly genotyped markers were associated with
severe diabetic retinopathy at a P-value less than .0001: SNP rs2300782 (P = 6.04 × 10
−5) mapped to an intron region of CAMK4
(calcium/calmodulin-dependent protein kinase IV) on chromosome 5, and SNP rs10519765 (P = 6.21 × 10
−5) on chromosomal
15q13 in the FMN1 (formin 1) gene. Using well-imputed markers based on the HapMap III Mexican population, we identiﬁed an
additional 32 SNPs located in 11 chromosomal regions with nominal association with severe diabetic retinopathy at P-value less
than .0001. None of these markers were located in traditional candidate genes for diabetic retinopathy or diabetes itself. However,
these signals implicate genes involved in inﬂammation, oxidative stress and cell adhesion for the development and progression of
diabetic retinopathy.
1.Introduction
Diabetic retinopathy is a common microvascular compli-
cation of diabetes and remains one of the leading causes
of blindness throughout the world [1]. It is estimated that
4.1 million Americans have diabetic retinopathy, which
causes 12,000 to 24,000 new cases of blindness every year
[2]. National Health Interview Survey and US census data
lead to projections that the number of Americans 40 years
or older having diabetic retinopathy will triple from 5.5
millions in 2005 to 16 millions in 2050 [3]. Although the
underlying mechanisms leading to diabetic retinopathy have
not been clariﬁed, many risk factors have been reported,
including poor glycemic control, longer diabetes duration,
hypertension, hyperlipidemia, and albuminuria [4–7]. Evi-
dence from ethnic and family studies has implicated genetic
susceptibility for diabetic retinopathy. Mexican-Americans
and African-Americans have been reported to have higher
prevalence and worse severity of diabetic retinopathy in the
US population when compared to non-Hispanic Whites [8,
9]. The Diabetes Control and Complications Trial (DCCT)
showed a 3.1 times increased risk of severe retinopathy2 Journal of Ophthalmology
for individuals with retinopathy-positive relatives, and a
correlation of retinopathy severity of 0.187 for all fam-
ily members [10]. Similar familial clustering of diabetic
retinopathy was also found among South Indians [11]a n d
Mexican-Americans [12] with type 2 diabetes. The FIND-
Eye study recently reported the broad sense heritability for
diabetic retinopathy as 27% overall and 24% in Mexican-
American families [13].
The suggestive genetic contribution to diabetic retinopa-
thy has lead to the search for candidate genes and for
genome-wide linkage between genetic markers and this
complex disease, but no conclusive loci have been identiﬁed
or replicated [14, 15]. Aﬀected sibpair analysis in Pima
Indians showed some evidence for linkage to diabetic
retinopathy on chromosome 3 and 9 [16], and another
signal on chromosome 1 was found in a subsequent study
of the same population [17]. Our group also performed
a linkage scan in Mexican-Americans from Starr County,
Texas,andproposed25potentialcandidategenesfordiabetic
retinopathyunderthelinkagepeaksonchromosome3,6,12,
15, 19, and 20 [18].
As linkage studies lack power to identify alleles with
modest eﬀects or those that interact with other genetic
or environmental factors on disease risk, genome-wide
association studies (GWASs) using dense sets of SNPs across
the genome have rapidly advanced our understanding of
the genetic background of complex diseases [19]. The Starr
County Health Studies has also reported GWAS results
for type 2 diabetes among Mexican-Americans [20]w i t h
supportive replications from other studies [21–23]. Utilizing
stereoscopic fundus photography within this population, we
present here the ﬁrst genome-wide association analysis of
diabetic retinopathy among Mexican-Americans with type 2
diabetes from Starr County, Texas.
2.MaterialsandMethods
2.1. Study Subjects. This study includes 286 individuals with
type 2 diabetes representing the earliest onset sibling having
fundus photography from sibships with two or more type
2 diabetes-aﬀected siblings from an ongoing genetic study
of diabetic retinopathy among Mexican-Americans in Starr
County,Texas[18,20].Baselinecharacteristicswereobtained
from personal interviews and physical examinations. Fasting
blood samples and urine specimens were collected for
glycemic, lipid, and microalbuminuria measurements, as
previously described [24].
2.2. Genotyping. DNA samples extracted from participants
were genotyped using the Aﬀymetrix GeneChip Human
Mapping 100K Set [20, 25]. Genotypes were called using
the GEL algorithm [26] given its improved call rate and
consistent results with other calling methods [20]. According
to the annotation ﬁle released in March, 2008 from the
Aﬀymetrix NetAﬀxA n a l y s i sC e n t e r( http://www.aﬀymetrix
.com/analysis/index.aﬀx) and the National Center of
Biotechnology Information (NCBI) Human Genome Build
36 data, we analyzed 112,666 autosomal SNPs that can be
mapped to the NCBI Entrez SNP database and also deﬁned
their associated genes in this mapping 100K set.
2.3. Diabetic Retinopathy Grading. All participants com-
pleted detailed ophthalmologic examinations including
stereoscopic color fundus photography of the seven standard
ﬁelds from the Diabetic Retinopathy Study (DRS) for each
eye [27]. Photographs were sent to the University of Wiscon-
sin Reading Center for examination and grading [28] using
the Early Treatment Diabetic Retinopathy Study (ETDRS)
adaptation of the modiﬁed Airlie House classiﬁcation system
[29]. The score for the more severely aﬀected eye of an
individual was used to classify retinopathy status. Since it has
been shown that familial factors seem to especially inﬂuence
the severity of diabetic retinopathy [10, 12], we focused
this analysis on severe diabetic retinopathy and deﬁned our
cases and controls as follows. ETDRS grade 10–37: normal
to early nonproliferative diabetic retinopathy (NPDR-E) as
controls, and 43–85: moderate-to-severe nonproliferative
diabetic retinopathy (NPDR-S) and proliferative diabetic
retinopathy (PDR) as cases.
2.4. Quality Control and Population Stratiﬁcation. Fisher’s
Exact tests of Hardy-Weinberg Equilibrium for controls
and for all samples, as well as χ2 tests for the distribution
of missing genotypes between cases and controls, were
conducted for all 112,666 autosomal SNPs. SNP quality was
also assessed based on genotype call rate and minor allele
frequency(MAF).Acomplete-linkagehierarchicalclustering
method implemented in PLINK [30]w a sc o n d u c t e dt o
exploreanypossiblesubstructureamongstudysubjectsusing
pairwise identity-by-state (IBS) distance across the genome-
wide SNP data. SNPs with a genotyping rate <95%, minor
allele frequencies <1% in all study subjects, and P-value
of exact Hardy-Weinberg Equilibrium test <.001 both in
the entire study subjects and control group were tagged for
potential quality control issues. A genomic inﬂation factor
(λ)[ 31]a n dm e a nχ2 statistics generated from all tested
SNPs were also calculated to evaluate the eﬀect of population
stratiﬁcation. The quantile-quantile plot of observed and
expected distributions of P-values was used to assess any
distortion of observed distribution from the null.
2.5. Imputation of Untyped SNPs. To expand the genomic
coverage, we applied a computationally eﬃcient hid-
den Markov Chain model [32] programmed in MACH
(http://www.sph.umich.edu/csg/abecasis/MACH/)[ 33]t o
impute autosomal genotypes that were present in HapMap
Phase III data in the Mexican population from Los Angeles,
California, but not genotyped in the Aﬀymetrix 100K
SNP set. An average allele dosage was estimated with 100
iterations of the imputation algorithm conditional on a set
of known haplotypes while simultaneously estimating the
recombination map. The squared correlation (r2)b e t w e e n
imputed and true genotypes was estimated for each SNP
to evaluate imputation performance [33]. The mask option
within MACH was also used to hide 2% of genotypes from
the haplotyping, and imputed genotypes at these locationsJournal of Ophthalmology 3
were compared with the actual genotypes to estimate the
imputation error rate.
2.6. Statistical Analysis. χ2 tests, Student T-tests, and logistic
regressions were used to compare the basic characteristics
between cases and controls using SAS/STAT system (SAS
Institute Inc., Cary, NC). For single-marker case-control
analyses, we did not initially ﬁlter any SNPs for quality-
control reasons, but we labeled them with quality-control
indicators for data interpretation. Logistic regression under
an additive genetic model was performed for each directly
genotyped SNP adjusting for the eﬀects of age, gender,
diabetes duration, and serum glycosylated hemoglobin level
using PLINK [30]. Imputed markers with poor performance
were ﬁltered to obtain more reliable association results based
on the per marker quality measures generated from MACH.
Ac u t o ﬀ of 0.5 for r2 between imputed and true genotypes
was applied to remove about 90% of poorly imputed SNPs at
a cost of 5% of good ones. To account for the probability dis-
tribution and the uncertainty of genotype imputation, logis-
tic regression modeling adjusted for the same covariates was
performed on these well-imputed markers using ProbABEL
(http://mga.bionet.nsc.ru/∼yurii/ABEL/) from the ABEL set
of programs [34, 35], where the SNP eﬀect was assessed by
its average imputed allele dosage.
3. Results
Among 286 Mexican-Americans with type 2 diabetes from
Starr County, Texas, 103 (36%) with severe nonproliferative
or proliferative diabetic retinopathy were deﬁned as cases.
Compared to those without retinopathy or only with modest
nonproliferativeretinopathy, individualswithseverediabetic
retinopathy had signiﬁcantly longer duration of diabetes,
higher glycohemoglobin levels, and higher systolic blood
pressure measurements (all P-values of Student t-test <.005,
Table 1)[ 36].
The average genotype call rate among study subjects was
93%, with 14% of the 112,666 autosomal SNPs having a
call rate less than 90%, and 4% having P-values for χ2 tests
for genotype missingness between cases and controls less
than .01. All polymorphic SNPs in this study (n = 111,528)
remained in the single-marker analysis, and 5641 (5%) of
them had minor allele frequency (MAF) less than 1%. The
mean χ2 statistics and the genomic inﬂation factor (λ)w e r e
1.02 and 1.06, respectively, suggesting that any observed
associations will unlikely be due to population stratiﬁcation.
However, there might be a slightly increased false positive
rate since both values are greater than 1. There was no
subpopulation identiﬁed from our study subjects using the
IBS clustering analysis, and none of the permutation tests of
IBS diﬀerences between cases and controls were signiﬁcant
(data not shown). The Q-Q plot in Supplementary Figure 1
also shows no strong evidence of population stratiﬁcation,
but with a deviation toward null possibly due to decreased
power.
Figure1showstheP-valuedistributionforsingle-marker
associations with severe retinopathy under an additive
genetic model adjusted for age, gender, diabetes duration,
and glycosylated hemoglobin level across the whole genome
using the Aﬀymetrix 100K SNP set. All the top signals met
all quality control criteria. Detailed information for the 10
strongest single marker associations is presented in Table 2.
(Results for all SNPs are available as Supplementary Table 1)
The best signals found in this study were rs2300782 (P =
6.04 × 10
−5) in 5q21 and rs10519765 (P = 6.21 × 10
−5)i n
15q13, that locate in the intron of the calcium/calmodulin-
dependent protein kinase IV (CAMK4) gene and formin 1
(FMN1) gene, respectively.
The 100K SNP set alone is insuﬃcient to cover most
variants currently available, therefore, we extended the
analysis to an imputation-based GWAS using HapMap data
[37]. To improve imputation performance, one subject with
an overall genotyping rate less than 90% and 8,094 SNPs
not meeting quality control criteria were excluded from
imputation. A total of 1,326,990 SNPs from the HapMap
Phase III Mexican population in Los Angeles, California,
were imputed on 102 cases and 183 controls of severe
diabetic retinopathy based on 104,572 directly genotyped
SNPs. Supplementary Table 2 summarizes the imputation
performance of MACH [33] across the whole genome. More
than 88% of the imputed SNPs had a minor allele frequency
greater than 1%, and the MACH estimated per allele error
rate after masking 2% of direct genotypes from imputation
was 8.7%. For all imputed markers, the overall r2 between
imputed and true genotypes was 0.387, and the average
posterior probability for the most likely genotypes was 0.783.
The 421,010 (31.7%) markers considered well imputed with
an r2 ≥ 0.5 were used for subsequent association analysis.
Figure 2 shows the genome-wide P-value distribution
from the logistic regression models using the well-imputed
SNPs. The genomic inﬂation factor (λ) and the mean χ2
statistics were 1.03 and 0.47, respectively, implying that
any observed associations are unlikely due to population
stratiﬁcation. Table 3 summarizes the genes nearest the top
signals (P-value less than 10
−4) under logistic regression
models adjusted for the eﬀects of age, gender, diabetes
duration, and glycosylated hemoglobin level. There were 32
SNPs associated with severe diabetic retinopathy at P-value
less than 10
−4, with 7 of these top signals in chromosomal
region 6p11-12, where tubulointerstitial nephritis antigen
(TINAG) is encoded.
4. Discussion
Genome-wide association studies provide an additional tool,
in conjunction with candidate gene and linkage studies
to better understand the genetics of diabetic retinopathy.
Our strongest signals from single-marker analysis implicated
several genes as associated with severe diabetic retinopathy.
SNP rs2300782 is located in an intronic region of CAMK4;
itsproducthasbeenreportedwithintheCa(2+)/calmodulin-
dependent protein kinase subfamily and has been shown to
increase transcriptional activity required for ATF-2 induced
insulin gene expression [38]. The second best single-marker
signal rs10519765 is located in FMN1, encoding a protein4 Journal of Ophthalmology
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Figure 1: Summary of genome-wide associations between 111,528 SNPs and severe diabetic retinopathy under additive genetic model
adjusted for age, gender, diabetes duration, and HbA1c level.
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Figure 2:Summaryofgenome-wideassociationsbetween421,010well-imputedSNPsandseverediabeticretinopathyunderadditivegenetic
model adjusted for age, gender, diabetes duration, and HbA1c level.Journal of Ophthalmology 5
Table 1: Basic characteristics of Mexican-Americans with type 2 diabetes from Starr County, Texas.
Variables N oD R+N P D R - E
# NPDR-S + PDR
# P-value
§ OR (95%CI)
(controls n = 183) (cases n = 103)
Age Mean ±SD 57.06 ±11.54 58.67 ±9.27 .1988 1.01 (0.99–1.04)
Gender Male 66 (36.07%) 43 (41.75%) .3422 1.00 —
Female 117 (63.93%) 60 (58.25%) 0.79 (0.48–1.29)
Albumin Negative 132 (74.58%) 57 (60.64%) .0802 1.00 —
20mg/L 22 (12.43%) 14 (14.89%) 1.47 (0.70–3.08)
50mg/L 17 (9.60%) 17 (18.09%) 2.32 (1.10–4.86)∗
100mg/L 6 (3.39%) 6 (6.38%) 2.32 (0.72–7.49)
Hypertension history No 96 (54.24%) 59 (59.60%) .3895 1.00 —
Yes 81 (45.76%) 40 (40.40%) 0.80 (0.49–1.32)
Diabetes duration (yrs) mean ±SD 12.02 ±9.09 18.10 ±8.22 <.0001 1.08 (1.05–1.11)∗∗∗
HbA1C (%) mean ±SD 10.87 ±3.72 12.29 ±3.90 .0028 1.10 (1.03–1.18)∗∗∗
Fasting glucose (mg/dL) mean ±SD 185.54 ±68.71 201.63 ±84.49 .0883 1.03 (0.99–1.06)
BMI (kg/m2) mean ±SD 31.82 ±6.49 30.85 ±5.93 .2175 0.98 (0.94–1.02)
Systolic BP (mmHg) mean ±SD 126.79 ±17.86 134.73 ±23.26 .0037 1.21 (1.07–1.38)∗∗∗
(every 10 unit)
Diastolic BP (mmHg) mean ±SD 72.69 ±10.03 73.32 ±10.78 .6290 1.06 (0.84–1.35)
(every 10 unit)
Total cholesterol (mg/dL) mean ±SD 191.21 ±41.81 199.06 ±42.13 .1381 1.05 (0.99–1.11)
(every 10 unit)
Triglycerides (mg/dL) mean ±SD 184.79 ±120.92 210.02 ±123.59 .1031 1.02 (0.99–1.04)
(every 10 unit)
HDL cholesterol (mg/dL) mean ±SD 42.86 ±11.73 40.62 ±10.32 .1153 0.83 (0.66–1.05)
(every 10 unit)
LDL cholesterol (mg/dL) mean ±SD 111.49 ±30.71 118.94 ±34.84 .0790 1.08 (0.99–1.16)
#No DR: normal or nondiabetic retinopathy; NPDR-E: early nonproliferative diabetic retinopathy
#NPDR-S: moderate-to-severe nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy
§P-value of χ2 test or Student t-test
∗P-value <. 05, ∗∗P-value <. 01, ∗∗∗P-value <. 005.
involved in cell adhesion and morphogenesis by assembling
radial action cablesin epithelial cells[39, 40]. However, there
is very limited evidence about genetic variation on CAMK4
or FMN1 and diabetes or its complications.
CNTN5 (contactin 5) at 11q22 is also among the nom-
inally associated genes for severe diabetic retinopathy. The
protein encoded by CNTN5 belongs to an immunoglobulin
superfamily and may participate in the developing nervous
system [41]. SNP variants in CNTN5 have been reported
to be associated with atrial ﬁbrillation and heart failure
[42]. Another top single-marker signal was in COLEC12
(collectin subfamily member 12), encoding a protein of
the C-lectin family, that possesses collagen-like sequences
and carbohydrate recognition domains. This protein is a
scavenger receptor recognizing oxidized phospholipids, so it
may participate in removing oxidative damage [43], which
is a potential etiological factor for diabetic retinopathy [44].
API5, EDIL3, BFSP2, HNMT, and SCYL1BP1 were also
amongthetopsignalsfromthesingle-markeranalysiswithin
their associated region, but there is no clear connection cur-
rently between these genes and diabetes or its complications.
Imputation of untyped SNP markers is as a useful
tool to improve the coverage and power for genome-wide
association studies without additional genotyping costs [45,
46]. A number of programs have been developed and
routinely used to impute genotypes based on the observed
haplotype structure from millions of SNPs in the HapMap
project[37]or1000GenomesProject[47].Giventheuneven
coverage of the genome by the Aﬀymertrix 100K SNP set,
a more detailed SNP map was obtained by imputation
conductedinMACH[32],sinceitconsistentlyoutperformed
other algorithms with better accuracy and eﬃciency [48, 49].
The Mexican-American population in Starr County is rel-
atively homogenous with 97.5% self-reporting as Hispanic.
Genetically, this population is admixed with 68% European,
27% Asian, and 6% African ancestry [20]. Considering the
importance of linkage disequilibrium pattern between the
reference panel and study subjects, we used the HapMap
III population with Mexican ancestry from Los Angles,
California, who identiﬁed themselves as having at least
three grandparents born in Mexico, as the reference set
for imputation. The overall 8.7% estimate from MACH of
overall allele error rate was comparable with the original
MACH evaluation data (7.5%) [32]. Compared to all the
autosomal SNP variants (n = 1,387,466) available in the
HapMap III Mexican population, the genomic coverage in6 Journal of Ophthalmology
Table 2: Top 10 single-marker associations with severe diabetic retinopathy among Mexican-Americans from Starr County, Texas.
dbSNP rs# Chr Position
∗ Minor/major
allele
MAF in
Cases
MAF in
Controls
P-value
§ OR
+
(95%CI)
Nearest gene∗
Distance/
relationship to
gene
rs2300782 5 110816684 A/G 0.512 0.322 6.04E −05 2.64
(1.64–4.25)
CAMK4 intron/0
rs10519765 15 30992716 A/G 0.136 0.294 6.21E −05 0.30
(0.16–0.54)
FMN1 intron/0
rs899036 11 41639486 C/A 0.125 0.210 2.52E −04 0.32
(0.17–0.59)
API5 upstream/
1650623
rs10501943 11 99452209 C/T 0.195 0.086 2.53E −04 3.04
(1.68–5.52)
CNTN5 intron/0
rs1445754 5 83611387 A/T 0.143 0.273 3.35E −04 0.37
(0.22–0.64)
EDIL3 intron/0
rs1197310 3 134610914 T/A 0.540 0.435 3.35E −04 2.25
(1.45–3.51)
BFSP2 intron/0
rs699549 2 4683138 T/C 0.115 0.043 3.49E −04 4.27
(1.93–9.47)
— —
rs763970 2 138352603 A/C 0.330 0.206 4.00E −04 2.25
(1.44–3.52)
HNMT upstream/
85675
rs599019 18 284495 G/T 0.030 0.131 4.06E −04 0.15
(0.05–0.43)
COLEC12 downstream/
24861
rs6427247 1 168647104 G/A 0.360 0.221 4.56E −04 2.17
(1.41–3.35)
SCYL1BP1 upstream/
120790
∗Aﬀymetrix NetAﬀx annotation build 25, NCBI genome build 36.1.
§P-value of logistic regression under additive genetic model, adjusted for age, gender, diabetes duration, and HbA1c level.
+odds ratios of the minor allele.
Table 3: Regions with strongest imputation-inferred associations (P<. 0001) using estimated allelic dosage under an adjusted additive
genetic model.
Location SNP with best P-value
within this region
Position
∗ Best P-value
§ # of top SNPs
within this region
Nearest gene∗
6p11-12 rs6909083 54290262 1.80E −05 7 TINAG
6q22 rs17083119 121443809 2.76E −05 4 C6orf170
1q23 rs1033465 171254353 4.50E −05 2 TNFSF18
1p13 rs11583330 109925036 5.35E −05 1 GNAI3
1q42 rs3014267 225619540 6.58E −05 1 CDC42BPA
15q13 rs11635920 30999949 7.18E −05 4 FMN1, GREM1
2q35-36 rs6726798 219009099 8.66E −05 1 VIL1
10q21 rs11812882 59712631 8.85E −05 1 ZCD1
2q35 rs1106412 219023301 8.91E −05 1 USP37
3p24 rs11927173 23200198 9.39E −05 2 UBE2E2
8q22 rs3098241 104494480 9.72E −05 2 SLC25A32
∗Aﬀymetrix NetAﬀx annotation build 25, NCBI genome build 36.1
§P-value of logistic regression under additive genetic model, adjusted for age, gender, diabetes duration, and HbA1C level.
the imputation analysis increases extensively with 30.3%
(n = 421,010) of the variants tested here, whereas only 4.3%
(n = 60,283) of them are directly covered in the Aﬀymetrix
100K SNP set.
Among all imputed markers associated with severe
diabetic retinopathy at a P-value less than 10
−4, there are
7 SNPs located in 6p11-12 where TINAG (tubulointerstitial
nephritis antigen) is encoded. TINAG is a glycoprotein
originally identiﬁed as a target antigen involved in human
antitubular basement membrane disease [50]. It has been
recognized as an extracellular matrix protein and shows
increased expression in the kidney of streptozotocin-diabetic
rats [51], but there is yet no evidence how TINAG might be
involved in human diabetes or its complications. Chromo-
somal region 15q13, where FMN1 (formin 1) and GREM1
(gremlin 1) map, also has 4 of the strongest imputation-
based signals. FMN1 has one of the strongest associations
from direct genotyping (rs10519765). Gremlin is locatedJournal of Ophthalmology 7
∼40kb downstream of FMN1, a highly conserved protein
involved in various disorders related to ﬁbrotic changes in
the kidney, lung, and liver [52]. This protein has been shown
to have a potential role in diabetic nephropathy because of
enhanced expression and interaction with TGF-β signaling
pathways [53, 54]. Recent evidence of increased gremlin
mRNA in bovine retinal perictyes [55] and immunohisto-
chemistry data on the mouse retina [54] coupled with results
reported here elevate interest in gremlin.
In addition to identifying novel candidate genes, we
were interested in SNPs among genes that appear to be
traditional candidates for diabetic retinopathy. A list of
208 retinopathy candidate genes has been generated [18,
56] (see Supplementary Table 3) to include genes involved
in metabolic processes or clinical risk factors leading to
retinopathy and those that have been previously reported
to be associated with diabetic retinopathy. Among a total of
667 SNPs that are located in the coding region of these 208
candidate genes and also genotyped in the Aﬀymetrix 100K
SNP set, 54 of them had nominal allelic association with
diabetic retinopathy with P-values ranging from .001 to .05
(Supplementary Figure 2). The signiﬁcance pattern found
here is more than expected by chance alone.
Although we cannot completely exclude the possibility
of undetected subpopulations aﬀecting the results, we found
no evidence of population stratiﬁcation. Hayes et al. also
used the genome-wide SNP data to estimate proportions
of ancestry on the same population. Ancestry is unlikely
to be a source of spurious association in this sample
since the amount of African, Asian, and European ances-
tries were indistinguishable between cases and controls
[20].
The primary objective of this study is searching for
diabeticretinopathygeneswithoutanyassumptionaboutthe
location of disease-associating variants. This initial genome-
wide association analysis of severe diabetic retinopathy
identiﬁed several unexpected loci that may contribute to
the genetic susceptibility of diabetic retinopathy. The study
was limited, however, in its ability to detect small eﬀect
sizes. A sample of 103 cases and 183 controls was only
powerful enough to identify variants with odds ratios greater
than 2.2 (assuming disease allele frequency of 0.5 and
disease prevalence of 0.5 in an additive model, calculated
by CaTS [57]) with a genome-wide signiﬁcance level (P-
value less than 5 × 10
−8). On the other hand, genetic
association studies usually require replication in appropriate
independent samples to validate any ﬁndings. No such
comparable data among Mexican-Americans are available
though we are expanding the sample and SNP coverage, even
so,theseresultssetsomelimitsastothemagnitudeofgenetic
eﬀects for diabetic retinopathy.
In summary, we observed several SNPs and genes associ-
ated with severe diabetic retinopathy in this initial genome-
wide analysis. None of these loci have been previously
linked to diabetic retinopathy or diabetes itself. While
the underlying mechanisms leading to diabetic retinopathy
remain unresolved, these results implicate genetic regulation
of oxidative stress and cell adhesion as possible players in the
development of diabetic retinopathy.
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